Logo image of ATNM

ACTINIUM PHARMACEUTICALS INC (ATNM) Stock Fundamental Analysis

NYSEARCA:ATNM - NYSE Arca - US00507W2061 - Common Stock - Currency: USD

1.21  -0.04 (-3.2%)

After market: 1.21 0 (0%)

Fundamental Rating

2

Taking everything into account, ATNM scores 2 out of 10 in our fundamental rating. ATNM was compared to 568 industry peers in the Biotechnology industry. The financial health of ATNM is average, but there are quite some concerns on its profitability. ATNM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ATNM had negative earnings in the past year.
ATNM had a negative operating cash flow in the past year.
In the past 5 years ATNM always reported negative net income.
ATNM had negative operating cash flow in 4 of the past 5 years.
ATNM Yearly Net Income VS EBIT VS OCF VS FCFATNM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

ATNM's Return On Assets of -49.73% is in line compared to the rest of the industry. ATNM outperforms 47.36% of its industry peers.
With a Return On Equity value of -116.74%, ATNM perfoms like the industry average, outperforming 41.73% of the companies in the same industry.
Industry RankSector Rank
ROA -49.73%
ROE -116.74%
ROIC N/A
ROA(3y)-46.19%
ROA(5y)-40.57%
ROE(3y)-100.2%
ROE(5y)-74.1%
ROIC(3y)N/A
ROIC(5y)N/A
ATNM Yearly ROA, ROE, ROICATNM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATNM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATNM Yearly Profit, Operating, Gross MarginsATNM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

4

2. Health

2.1 Basic Checks

ATNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ATNM has more shares outstanding
Compared to 5 years ago, ATNM has more shares outstanding
ATNM has a better debt/assets ratio than last year.
ATNM Yearly Shares OutstandingATNM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ATNM Yearly Total Debt VS Total AssetsATNM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -7.10, we must say that ATNM is in the distress zone and has some risk of bankruptcy.
ATNM has a worse Altman-Z score (-7.10) than 66.55% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that ATNM is not too dependend on debt financing.
ATNM's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. ATNM outperforms 49.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.1
ROIC/WACCN/A
WACC10.32%
ATNM Yearly LT Debt VS Equity VS FCFATNM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

ATNM has a Current Ratio of 9.14. This indicates that ATNM is financially healthy and has no problem in meeting its short term obligations.
ATNM has a Current ratio of 9.14. This is in the better half of the industry: ATNM outperforms 76.41% of its industry peers.
A Quick Ratio of 9.14 indicates that ATNM has no problem at all paying its short term obligations.
ATNM has a Quick ratio of 9.14. This is in the better half of the industry: ATNM outperforms 76.41% of its industry peers.
Industry RankSector Rank
Current Ratio 9.14
Quick Ratio 9.14
ATNM Yearly Current Assets VS Current LiabilitesATNM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 30.98% over the past year.
Looking at the last year, ATNM shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)30.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.24%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 11.29% on average over the next years. This is quite good.
The Revenue is expected to grow by 268.55% on average over the next years. This is a very strong growth
EPS Next Y25.4%
EPS Next 2Y5%
EPS Next 3Y5.05%
EPS Next 5Y11.29%
Revenue Next Year16957.1%
Revenue Next 2Y-50.18%
Revenue Next 3Y353.29%
Revenue Next 5Y268.55%

3.3 Evolution

ATNM Yearly Revenue VS EstimatesATNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
ATNM Yearly EPS VS EstimatesATNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ATNM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ATNM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATNM Price Earnings VS Forward Price EarningsATNM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATNM Per share dataATNM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5%
EPS Next 3Y5.05%

More info and screens

0

5. Dividend

5.1 Amount

ATNM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACTINIUM PHARMACEUTICALS INC

NYSEARCA:ATNM (4/17/2025, 8:04:00 PM)

After market: 1.21 0 (0%)

1.21

-0.04 (-3.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-01 2025-04-01/bmo
Earnings (Next)04-24 2025-04-24
Inst Owners29.62%
Inst Owner Change0%
Ins Owners1.79%
Ins Owner Change0%
Market Cap37.75M
Analysts81.82
Price Target5.1 (321.49%)
Short Float %7.33%
Short Ratio11.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)18.5%
Min EPS beat(2)-7.96%
Max EPS beat(2)44.95%
EPS beat(4)3
Avg EPS beat(4)21.64%
Min EPS beat(4)-7.96%
Max EPS beat(4)44.95%
EPS beat(8)6
Avg EPS beat(8)14.55%
EPS beat(12)7
Avg EPS beat(12)-5.01%
EPS beat(16)9
Avg EPS beat(16)-3.81%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)15.79%
EPS NQ rev (3m)45.76%
EPS NY rev (1m)0%
EPS NY rev (3m)-34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-12.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.15
P/tB 1.15
EV/EBITDA N/A
EPS(TTM)-1.27
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-1.06
FCFYN/A
OCF(TTM)-1.06
OCFYN/A
SpS0
BVpS1.05
TBVpS1.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -49.73%
ROE -116.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.19%
ROA(5y)-40.57%
ROE(3y)-100.2%
ROE(5y)-74.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.36%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.14
Quick Ratio 9.14
Altman-Z -7.1
F-Score3
WACC10.32%
ROIC/WACCN/A
Cap/Depr(3y)24.36%
Cap/Depr(5y)31.01%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.24%
EPS Next Y25.4%
EPS Next 2Y5%
EPS Next 3Y5.05%
EPS Next 5Y11.29%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year16957.1%
Revenue Next 2Y-50.18%
Revenue Next 3Y353.29%
Revenue Next 5Y268.55%
EBIT growth 1Y18.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.21%
EBIT Next 3Y-3.41%
EBIT Next 5Y-5.71%
FCF growth 1Y30.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.13%
OCF growth 3YN/A
OCF growth 5YN/A